Three biotech stocks have plenty of potential, John Schroer of Allianz Global Investors says.» Read More
Amgen Inc. rose$. 51 or. 4 percent, to $138.47. Biogen Idec rose$. 64 or. 2 percent, to $343.32. Celgene Corp. fell$. 31 or. 3 percent, to $94.78.
Amgen Inc. rose$. 62 or. 4 percent, to $138.58. Biogen Idec rose $1.16 or. 3 percent, to $343.84. Celgene Corp. rose$. 15 or. 2 percent, to $95.24.
Amgen Inc. fell $1.42 or 1.0 percent, to $137.96. Biogen Idec fell$. 36 or. 1 percent, to $342.68. Celgene Corp. rose$. 07 or. 1 percent, to $95.09.
Amgen Inc. fell $2.00 or 1.4 percent, to $137.38. Biogen Idec fell $1.86 or. 5 percent, to $341.18. Celgene Corp. fell$. 00 or percent, to $95.02.
Aug 27- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.
Bankers and lawyers providing takeover advice said on Monday that Burger King Worldwide Inc's intention to move its tax domicile overseas through a so-called inversion deal- in this case the purchase of Canada's Tim Hortons- shouldn't be seen as a sign of a lot more deals to come.
Aug 21- Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.
CNBC's Meg Tirrell explains what ALS, or Lou Gehrig's disease is, and what is known about treating the disease.
Cramer often look inside the market for insights on broad sentiment. And certain things happened on Wednesday that suggest trouble.
U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.
NEW YORK, Aug 13- U.S. stocks rose on Wednesday, with the Dow returning to positive territory for the year as the market shrugged off weak earnings reports and a slump in retail shares. Biotech shares surged, with the Nasdaq biotech index climbing 2.1 percent on the back of stocks including InterMune Inc and Jazz Pharmaceuticals PLC.
Propelled by Facebook and Twitter, the ice bucket challenge has become a viral sensation. Now Biogen executives and CNBC are rising to the challenge.
CNBC's Scott Wapner accepted the "ice bucket challenge" on "Fast Money Halftime Report." Wapner passed it on to Mark Zuckerberg and Dick Costolo.
CNBC's Scott Wapner accepts the "ice bucket challenge" from Biogen Idec's Doug Williams on "Fast Money Halftime Report." He then passes it to Facebook CEO Mark Zuckerberg and Twitter CEO Dick Costolo. Trader Pete Najarian shares the story of his brother Paul who passed from ALS.
Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.
July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.
If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.
*Apple rallies after results, boosting tech names. NEW YORK, July 23- U.S. stocks ended mostly higher on Wednesday, with the S&P 500 closing at a record on Apple's bullish results, though Boeing weighed on the Dow and conflicts in Ukraine and the Gaza Strip kept the broader market's gains in check.
U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.
*Apple rallies after results, boosting tech names. NEW YORK, July 23- U.S. stocks were largely higher on Wednesday, with the S&P 500 hitting another record high after bullish results from tech giants Apple and Microsoft, though technical resistance and conflicts in Ukraine and the Gaza Strip kept gains in check.